![ASCO 2020: AGO DESKTOP III Highlights Importance of Complete Resection in Recurrent Ovarian Cancer | PracticeUpdate ASCO 2020: AGO DESKTOP III Highlights Importance of Complete Resection in Recurrent Ovarian Cancer | PracticeUpdate](https://d2ogjlfjkptkow.cloudfront.net/contentimage/25597.jpg)
ASCO 2020: AGO DESKTOP III Highlights Importance of Complete Resection in Recurrent Ovarian Cancer | PracticeUpdate
![توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk» توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk»](https://pbs.twimg.com/media/EZSnPKNWoAExnUV.jpg)
توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk»
![Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer](https://larvolclin.s3.us-west-2.amazonaws.com/resize_1654681337201740336562a06ef979af6.png)
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
![Mauricio Lema-Medina on Twitter: "#esmo17 -DESKTOP III: Only potential R0 resection (<500 mL ascites, Good PS, Optimal 1ry debulking) should undergo 2ry cytoreduction in OvCa https://t.co/WP7uHBw4pr" / Twitter Mauricio Lema-Medina on Twitter: "#esmo17 -DESKTOP III: Only potential R0 resection (<500 mL ascites, Good PS, Optimal 1ry debulking) should undergo 2ry cytoreduction in OvCa https://t.co/WP7uHBw4pr" / Twitter](https://pbs.twimg.com/media/DJSY-lSXUAAUS2v.jpg)
Mauricio Lema-Medina on Twitter: "#esmo17 -DESKTOP III: Only potential R0 resection (<500 mL ascites, Good PS, Optimal 1ry debulking) should undergo 2ry cytoreduction in OvCa https://t.co/WP7uHBw4pr" / Twitter
![توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk» توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk»](https://pbs.twimg.com/media/EZSmC5NXQAIuBCf.jpg)
توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk»
![Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download](https://slideplayer.com/slide/6837466/23/images/62/AGO-OVAR+DESKTOP+III+%28Protocol+AGO-+OVAR+OP.4%29.jpg)
Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
![Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer](https://larvolclin.s3.us-west-2.amazonaws.com/resize_162187504565736430860abd965332f4.png)
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
![Fumiko Ladd Chino, MD Twitter'da: "🚨@Oncoalert: Dr Helen MacKay summarizes #gyncsm highlights including Desktop III (compared to Soc-1 and GOG-213) for recurrent epithelial #ovariancancer showing a 7.7 month OS benefit from 2ndary Fumiko Ladd Chino, MD Twitter'da: "🚨@Oncoalert: Dr Helen MacKay summarizes #gyncsm highlights including Desktop III (compared to Soc-1 and GOG-213) for recurrent epithelial #ovariancancer showing a 7.7 month OS benefit from 2ndary](https://pbs.twimg.com/media/EZSq8XHXkAAVLo9.jpg)